VZVC’s $4 billion biotech fund shifts away from funding dozens of startups annually
Vijay Pande’s new venture, VZVC, rejects the traditional venture capital approach of backing multiple biotech companies each year. Instead, it focuses on a precision-driven model that treats biology not as a field of discovery but as an engineering discipline. The transition from chance-driven research—where scientists identify proteins or molecules through observation—to AI-powered design marks a fundamental change in how biological problems are approached.
Two persistent obstacles remain even for advanced AI systems. First, the clinical trial process creates an insurmountable bottleneck: no amount of computational speed can accelerate the slow, high-cost, and regulatory-heavy process of validating drugs in humans. Second, the conflict between proprietary data hoarding and open datasets persists, with many companies viewing exclusive data as their strongest competitive advantage. Pande argues that shared, high-quality datasets are the key to unlocking AI’s full potential in medicine.
For biology to function like engineering, standardized and accessible data is essential. Engineering relies on consistent, reproducible inputs; when labs restrict data access, it becomes impossible to train models capable of capturing the complexity of biological systems. This reality cuts through the hype around AI in biotech, emphasizing that success depends on data infrastructure rather than refined prompts or protein design algorithms.
The most effective AI-driven biology projects will likely combine open-source datasets with collective intelligence, transforming the research process from trial-and-error experimentation to deliberate, iterative construction. The shift from passive observation to active engineering remains the defining challenge.
All Replies （4）
Want a live back-and-forth? Join the global AI chat room — login to talk.
Wild that he ignored how hardware moats are completely rewriting startup valuation models right now, especially since biology is moving from a “discovery” science to an “engineering” discipline.
The shift toward precision investing, like Vijay Pande’s focus on deep research with VZVC, is reshaping biotech—where funds now prioritize fewer, higher-impact bets over scattered bets. While AI accelerates drug discovery, the clinical trial bottleneck remains a critical hurdle, as even groundbreaking AI models can’t bypass the slow, costly validation needed to bring therapies to market.
Deep tech vetting is brutal—especially when you’re trying to cut through the noise without falling into the "spray and pray" trap. One concrete way to narrow the field is to focus on startups that aren’t just chasing incremental tweaks to existing biology but are actually engineering solutions from first principles, like how Vijay Pande’s VZVC prioritizes teams leveraging AI to design novel biological systems rather than just optimizing what’s already known. Beyond that, though, which specific metrics are you actually using to separate the signal from the hype?
Curious about this shift. Does he believe specialized labs have the edge over general compute clusters? Vijay Pande isn't interested in the traditional venture‑capital playbook of sprinkling money across thirty different companies each year just to see which one sticks. After steering a massive $4 billion biotech fund at a16z, he has shifted to a far more concentrated approach with his new AI‑native venture, VZVC. His thesis marks a sharp break from the “spray and pray” method, emphasizing precision and the fundamental change underway in how we tackle biological complexity. The heart of his argument lies in a massive paradigm shift: biology is moving from a “discovery” science to an “engineering” discipline. For decades, biology meant stumbling upon things—finding a protein that does X or a molecule that reacts with Y. It was observational and, frankly, quite messy. But with deep learning and massive compute woven in, we are heading toward a world where we can design biological outcomes from the ground up. We aren’t just looking for what exists; we are building what we need. Yet this transition isn’t free of massive friction points that even the top LLM agents or protein‑folding models can’t erase overnight. Pande highlights two massive hurdles that every AI‑driven biotech startup will eventually encounter: - The Clinical Trial Bottleneck: Even if an AI can conjure a perfect drug candidate in seconds, the physical reality of human biology remains agonizingly slow and brutally costly. The regulatory and biological validation process is a hard ceiling that software alone can't overcome.